Amicus Therapeutics, Inc. (FOLD) Issues Earnings Results, Beats Estimates By $0.03 EPS
Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its earnings results on Monday. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03, MarketWatch Earnings reports. During the same period last year, the firm posted ($0.40) earnings per share.
Shares of Amicus Therapeutics (FOLD) traded up 5.06% on Monday, hitting $13.90. The company’s stock had a trading volume of 3,148,423 shares. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.05. The stock’s market capitalization is $1.99 billion. The stock’s 50 day moving average price is $11.40 and its 200 day moving average price is $8.12.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Issues Earnings Results, Beats Estimates By $0.03 EPS” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/amicus-therapeutics-inc-nasdaqfold-posts-earnings-results-beats-estimates-by-0-02-eps.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Hung Do sold 29,914 shares of the company’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the sale, the insider now owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.
A number of large investors have recently modified their holdings of FOLD. Trexquant Investment LP acquired a new stake in shares of Amicus Therapeutics during the first quarter worth about $496,000. UBS Asset Management Americas Inc. boosted its stake in shares of Amicus Therapeutics by 71.8% in the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock worth $361,000 after buying an additional 21,174 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Amicus Therapeutics by 12.5% in the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock worth $4,794,000 after buying an additional 74,700 shares in the last quarter. Princeton Alpha Management LP acquired a new stake in shares of Amicus Therapeutics during the first quarter worth about $106,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Amicus Therapeutics during the first quarter worth about $7,346,000.
FOLD has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 16th. Robert W. Baird lifted their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. ValuEngine upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Bank of America Corporation reduced their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $13.42.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.